3 results on '"Christopher R. Braden"'
Search Results
2. Botulism in 4 Adults Following Cosmetic Injections With an Unlicensed, Highly Concentrated Botulinum Preparation
- Author
-
Joann Schulte, Steven M. Marcus, Jeremy Sobel, Jean M. Malecki, Daniel S. Chertow, Susan E. Maslanka, Eddy A. Bresnitz, Christopher R. Braden, Jeffrey N. Bernstein, Richard Weisman, Esther T. Tan, and Savita Kumar
- Subjects
Drug ,media_common.quotation_subject ,Iatrogenic Disease ,Cosmetic Techniques ,Pharmacology ,medicine.disease_cause ,Vial ,Median lethal dose ,Microbiology ,Lethal Dose 50 ,medicine ,Cluster Analysis ,Humans ,Botulism ,Botulinum Toxins, Type A ,media_common ,Toxin ,business.industry ,Lethal dose ,General Medicine ,Legislation, Drug ,medicine.disease ,Botulinum toxin ,United States ,Clostridium botulinum ,business ,medicine.drug - Abstract
ContextBotulism is a potentially lethal paralytic disease caused primarily by toxins of the anaerobic, spore-forming bacterium Clostridium botulinum. Although botulinum toxin A is available by prescription for cosmetic and therapeutic use, no cases of botulism with detectable serum toxin have previously been attributed to cosmetic or therapeutic botulinum toxin injections. On November 27, 2004, 4 suspected botulism case-patients with a link to cosmetic botulinum toxin injections were reported to the Centers for Disease Control and Prevention.ObjectiveTo investigate the clinical, epidemiological, and laboratory aspects of 4 suspected cases of iatrogenic botulism.Design, Setting, and PatientsCase series on 4 botulism case-patients.Main Outcome MeasuresClinical characteristics of the 4 case-patients, epidemiological associations, and mouse bioassay neutralization test results from case-patient specimens and a toxin sample.ResultsClinical characteristics of the 4 case-patients were consistent with those of naturally occurring botulism. All case-patients had been injected with a highly concentrated, unlicensed preparation of botulinum toxin A and may have received doses 2857 times the estimated human lethal dose by injection. Pretreatment serum toxin levels in 3 of the 4 case-patients were equivalent to 21 to 43 times the estimated human lethal dose; pretreatment serum from the fourth epidemiologically linked case-patient was not available. A 100-μg vial of toxin taken from the same manufacturer's lot as toxin administered to the case-patients contained a toxin amount sufficient to kill approximately 14 286 adults by injection if disseminated evenly.ConclusionsThese laboratory-confirmed cases of botulism demonstrate that clinical use of unlicensed botulinum toxin A can result in severe, life-threatening illness. Further education and regulation are needed to prevent the inappropriate marketing, sale, and clinical use of unlicensed botulinum toxin products.
- Published
- 2006
- Full Text
- View/download PDF
3. Transmission of Mycobacterium tuberculosis From Medical Waste
- Author
-
A. Yvonne Boudreau, Kammy R. Johnson, Thomas A. Bell, Sarah E. Valway, Kimberly W. Field, Glenn P. Morlock, Christopher R. Braden, Angela M. Weber, Paul A. Stehr-Green, A. Craig Craig Colombel, Charles L. Woodley, Zhenhua Yang, K. Lisa Cairns, and Ida M. Onorato
- Subjects
Tuberculosis ,biology ,business.industry ,Transmission (medicine) ,Medical record ,Tuberculin ,General Medicine ,Drug resistance ,medicine.disease ,biology.organism_classification ,law.invention ,Mycobacterium tuberculosis ,DNA profiling ,law ,Environmental health ,Immunology ,Medicine ,business ,Polymerase chain reaction - Abstract
ContextWashington State has a relatively low incidence rate of tuberculosis (TB) infection. However, from May to September 1997, 3 cases of pulmonary TB were reported among medical waste treatment workers at 1 facility in Washington. There is no previous documentation of Mycobacterium tuberculosis transmission as a result of processing medical waste.ObjectiveTo identify the source(s) of these 3 TB infections.Design, Setting, and ParticipantsInterviews of the 3 infected patient-workers and their contacts, review of patient-worker medical records and the state TB registry, and collection of all multidrug-resistant TB (MDR-TB) isolates identified after January 1, 1995, from the facility's catchment area; DNA fingerprinting of all isolates; polymerase chain reaction and automated DNA sequencing to determine genetic mutations associated with drug resistance; and occupational safety and environmental evaluations of the facility.Main Outcome MeasuresPrevious exposures of patient-workers to TB; verification of patient-worker tuberculin skin test histories; identification of other cases of TB in the community and at the facility; drug susceptibility of patient-worker isolates; and potential for worker exposure to live M tuberculosis cultures.ResultsAll 3 patient-workers were younger than 55 years, were born in the United States, and reported no known exposures to TB. We did not identify other TB cases. The 3 patient-workers' isolates had different DNA fingerprints. One of 10 MDR-TB catchment-area isolates matched an MDR-TB patient-worker isolate by DNA fingerprint pattern. DNA sequencing demonstrated the same rare mutation in these isolates. There was no evidence of personal contact between these 2 individuals. The laboratory that initially processed the matching isolate sent contaminated waste to the treatment facility. The facility accepted contaminated medical waste where it was shredded, blown, compacted, and finally deactivated. Equipment failures, insufficient employee training, and respiratory protective equipment inadequacies were identified at the facility.ConclusionProcessing contaminated medical waste resulted in transmission of M tuberculosis to at least 1 medical waste treatment facility worker.
- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.